Shares of Novavax, Inc. (NASDAQ:NVAX – Get Free Report) have been given a consensus rating of “Hold” by the ten analysts that are covering the company, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $12.33.
NVAX has been the subject of a number of recent research reports. Wall Street Zen upgraded Novavax from a “sell” rating to a “hold” rating in a report on Saturday, September 12th. Citigroup reaffirmed a “sell” rating and set a $8.00 target price (up from $7.00) on shares of Novavax in a research report on Thursday, October 15th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Novavax in a report on Monday. Zacks Research downgraded Novavax from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 6th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Novavax in a research report on Tuesday, October 27th.
View Our Latest Report on NVAX
Key Stories Impacting Novavax
Here are the key news stories impacting Novavax this week:
- Positive Sentiment: Novavax raised its 2026 adjusted revenue guidance by $145 million, to $385 million–$415 million (about $400 million at the midpoint), modestly above analyst consensus. It also lowered the midpoint of its combined R&D and SG&A expense outlook by $5 million. Reuters article
- Positive Sentiment: Third-quarter revenue of $68.3 million exceeded the roughly $50.4 million consensus, while the loss of $0.19 per share was narrower than expected. The results helped drive positive attention around the earnings release. MarketBeat earnings report
- Positive Sentiment: A $125 million milestone payment from Sanofi, earned after it began a European Phase 3 trial of its flu-COVID combination vaccine, materially supported the quarter. Sanofi also intends to start a U.S. Phase 3 trial in 2027; Novavax says it is targeting a cash runway into 2029. Novavax results release
- Negative Sentiment: Revenue was still down 3% year over year, and Novavax continues to report losses. The large Sanofi milestone also means the stronger outlook depends in part on licensing and milestone revenue, rather than demonstrating broad-based growth in recurring sales. Yahoo Finance article
Novavax Price Performance
NVAX opened at $9.78 on Friday. Novavax has a fifty-two week low of $6.20 and a fifty-two week high of $13.39. The firm has a market capitalization of $1.61 billion, a price-to-earnings ratio of -6.43 and a beta of 2.65. The company’s 50 day moving average price is $10.52 and its two-hundred day moving average price is $9.33.
Novavax (NASDAQ:NVAX – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.16. The firm had revenue of $68.30 million during the quarter, compared to the consensus estimate of $50.42 million. Novavax had a negative net margin of 59.87% and a negative return on equity of 14.82%. The company’s revenue for the quarter was down 3.0% on a year-over-year basis. During the same quarter last year, the firm earned ($1.25) earnings per share. As a group, equities research analysts predict that Novavax will post -0.38 EPS for the current year.
Hedge Funds Weigh In On Novavax
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Fulcrum Asset Management LLP acquired a new stake in shares of Novavax during the third quarter worth $181,000. Allspring Global Investments Holdings LLC raised its stake in Novavax by 4.5% during the third quarter. Allspring Global Investments Holdings LLC now owns 27,820 shares of the biopharmaceutical company’s stock worth $295,000 after buying an additional 1,207 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in Novavax during the third quarter worth $91,000. China Universal Asset Management Co. Ltd. lifted its holdings in Novavax by 15.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 30,096 shares of the biopharmaceutical company’s stock valued at $326,000 after buying an additional 3,926 shares during the period. Finally, Vontobel Holding Ltd. lifted its holdings in Novavax by 9.0% in the third quarter. Vontobel Holding Ltd. now owns 65,260 shares of the biopharmaceutical company’s stock valued at $705,000 after buying an additional 5,395 shares during the period. 53.04% of the stock is owned by institutional investors and hedge funds.
About Novavax
Novavax, Inc is a biotechnology company focused on developing and commercializing vaccines for infectious diseases. The company uses recombinant protein nanoparticle technology and its proprietary Matrix-M adjuvant to develop vaccines designed to stimulate targeted immune responses.
Novavax’s principal commercial product is Nuvaxovid, also known as the Novavax COVID-19 vaccine, a protein-based vaccine developed to help prevent COVID-19. The vaccine has been authorized or approved in various markets, subject to local regulatory requirements, and the company has worked with governments, public-health organizations, and pharmaceutical partners to support its distribution internationally.
Founded in 1987, Novavax is headquartered in Gaithersburg, Maryland.
Featured Stories
- Five stocks we like better than Novavax
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.
